Summit Therapeutics (SMMT) Invested Capital (2016 - 2025)
Historic Invested Capital for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $192.3 million.
- Summit Therapeutics' Invested Capital fell 5609.63% to $192.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.3 million, marking a year-over-year decrease of 5609.63%. This contributed to the annual value of $388.7 million for FY2024, which is 40037.07% up from last year.
- Latest data reveals that Summit Therapeutics reported Invested Capital of $192.3 million as of Q3 2025, which was down 5609.63% from $259.4 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Invested Capital registered a high of $437.9 million during Q3 2024, and its lowest value of $44.2 million during Q1 2024.
- Over the past 5 years, Summit Therapeutics' median Invested Capital value was $119.6 million (recorded in 2023), while the average stood at $159.9 million.
- In the last 5 years, Summit Therapeutics' Invested Capital tumbled by 6687.94% in 2024 and then skyrocketed by 67885.09% in 2025.
- Summit Therapeutics' Invested Capital (Quarter) stood at $83.3 million in 2021, then soared by 52.07% to $126.7 million in 2022, then tumbled by 38.66% to $77.7 million in 2023, then surged by 400.37% to $388.7 million in 2024, then crashed by 50.54% to $192.3 million in 2025.
- Its Invested Capital was $192.3 million in Q3 2025, compared to $259.4 million in Q2 2025 and $344.3 million in Q1 2025.